In a recent article, the authors evaluated the engraftment of six PDXs into prkdc−/−, il2rga−/− immune-compromised zebrafish, including one therapy-resistant ER+/PR+/Her2−, ILC derived from circulating tumor cells (CTCs) (BRx-07), which harbors activating mutations in PIK3CA and FGFR2 [190,191]. The gene discussed is ESR1; the disease is neoplasm.